Table 2.
Patterns of anti‐Parkinson drug use and choice among Medicare beneficiaries, 2007–2010
| Variable | Year | |||
|---|---|---|---|---|
| 2007 | 2008 | 2009 | 2010 | |
| Total no. of patients with PD cases | 9482 | 9626 | 9566 | 9503 |
| No. of anti‐Parkinson drug users | 7721 | 7872 | 7835 | 7725 |
| Use of any anti‐Parkinson drug, % | 81 | 82 | 82 | 81 |
| Levodopa use, % | 90 | 90 | 90 | 90 |
| Dopamine agonist use, % | 31 | 31 | 30 | 29 |
| MAOB inhibitor use, % | 9 | 9 | 10 | 11 |
| Anticholinergic use, % | 6 | 6 | 6 | 5 |
| Amantadine use, % | 8 | 7 | 7 | 7 |
| COMT inhibitor use, % | 8 | 7 | 7 | 6 |
PD, Parkinson's disease; MAOB, monoamine oxidase‐B; COMT, catechol‐O‐methyltransferase.